Steven Cantor New Jersey was the founder, Chairman of the Board, and CEO of Vasomedical, Inc., developer of an innovative heart disease device used in prestigious medical centers around the world, such as The Mayo Clinic,and The Miami Heart Institute. Vasomedical Inc. provides superior medical products and services that address unmet clinical needs in the managementof patients with heart disease
Technological and clinical advancement led to the development of EECP -Enhanced External Counterpulsation, the therapeutic systems exclusively designed and manufactured by Vasomedical with sequential pneumatic compression to increase retrograde diastolic flow, venous return and systolic unloading, greatly improve the ease of use, patient safety and clinical effectiveness.
Steven Cantor New Jersey traveled to the Sun Yat-sen Medical University in Guangzhou, China to conduct due diligence on a non invasive device for the treatment of heart disease that subsequently received United States
Food and Drug Administration (FDA) approval and was launched worldwide and described as a major medical breakthrough in heart disease. Known as the Enhanced External Counter Pulsation (EECP) treatment for coronary artery disease it is used worldwide in over 1,000 centers including at the Mayo Clinic, the Cleveland Clinic, Beth Israel Medical Center, Johns Hopkins,the Ochsner Foundation Hospital, The Miami Heart Institute, Scripps Center for Integrative Medicine and the Texas Heart Institute.
